Vernalis achieves milestone in oncology drug discovery collaboration with Servier

Vernalis and Servier have been working in partnership using Vernalis' proprietary fragment and structure-based drug discovery platform on a number of oncology targets, including Bcl-2 and Mcl-1. This milestone relates to success against an undisclosed target.

Under this collaboration Vernalis receives fees for work undertaken and milestones and royalties on sales on products as they progress.  The financial terms of the agreement covering this collaboration have not been disclosed.

Vernalis CEO Ian Garland said: "We are extremely pleased to achieve another milestone from this very successful partnership with Servier and we look forward to further success from this relationship."

Dr. Jean-Pierre Abastado, Director of the Oncology Innovation Therapeutic Pole for Servier added: "The collaboration between Servier and Vernalis has been extremely successful, relying on Vernalis expertise in Structural Biology and Chemistry and Servier expertise in Chemistry and Pharmacology.

"Over the years, strong and fruitful relationships have been built between the two teams."